NSE · ONYX · Pharmaceuticals
Onyx Biotec Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹63 Cr with net profit ₹5 Cr — a 7.85% net margin, versus 6.75% the period before.
Shareholding
As of 2026-03-31
- Promoter65.1%
- Public31.44%
- FII1.07%
- DII2.39%
586 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.23× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #1 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,73,341 Cr | 38.08 | 5.66 | 13.74% | 19.72% |
| Cipla Ltd. | ₹1,19,739 Cr | 215.75 | 3.48 | 11.27% | 14% |
| Zydus Lifesciences Ltd. | ₹1,12,249 Cr | 20.66 | 4.14 | 18.59% | 18.86% |
| Lupin Limited | ₹1,11,853 Cr | 70.24 | 4.98 | 23.76% | 19.4% |
| Mankind Pharma Limited | ₹1,07,656 Cr | 193.95 | 6.6 | 11.74% | 13.4% |
| Laurus Labs Limited | ₹96,235 Cr | 344.55 | 18.14 | 16.77% | 13.05% |
| Dr Reddys Laboratories Ltd. | ₹94,977 Cr | 429.4 | 2.51 | 0.11% | 0.12% |
| Aurobindo Pharma Ltd. | ₹92,574 Cr | 100.5 | 2.44 | 9.25% | 10.5% |
| Biocon Ltd. | ₹69,731 Cr | 544.56 | 2.05 | 1.14% | 2.3% |
| Alkem Laboratories Ltd. | ₹67,961 Cr | 287.51 | 4.92 | 16.66% | 15.65% |
| Onyx Biotec Limited(this company) | — | 21.25 | 1.4 | — | — |
AI analysis
AI-generated · google/gemini-2.5-flashOnyx Biotec Limited, operating in the Pharmaceuticals sector, has not specified its business activities. The company reported a 52-week high of Rs 53.9 and a 52-week low of Rs 24.2. Its book value per share is Rs 30.56. As of March 31, 2026, promoter shareholding stood at 65.0952%.
Positives
- +Promoter holding has been consistent at 65.0952% from November 2024 to March 2026, indicating stable leadership.
- +Debt-to-equity ratio is 0.53, suggesting moderate leverage.
- +Promoter pledge is 0%, indicating no pledged shares by promoters.
- +Annual revenue grew to Rs 63.1188 Cr in March 2025 from Rs 53.8743 Cr in March 2024.
- +Annual net profit increased to Rs 4.9542 Cr in March 2025 from Rs 3.6346 Cr in March 2024.
Negatives
- −Current EPS is negative at Rs -0.12, indicating recent losses.
- −No market capitalization data is available, making valuation difficult.
- −No dividend yield is available, so the company's dividend policy cannot be assessed.
- −No quarterly results have been disclosed since March 2026.
Financial performance
In the fiscal year ending March 2025, Onyx Biotec Limited recorded revenue of Rs 63.1188 Cr, an increase from Rs 53.8743 Cr in March 2024. Net profit for March 2025 was Rs 4.9542 Cr, up from Rs 3.6346 Cr in March 2024. Earnings per share (EPS) also rose to Rs 3.31 in March 2025 from Rs 3.05 in March 2024.
Profitability & returns
The company's Return on Capital Employed (ROCE) is 12.15%. While annual EPS for March 2025 was positive at Rs 3.31, the trailing twelve months EPS is negative at Rs -0.12. No data for Return on Equity (ROE) is available.
Balance sheet
Onyx Biotec Limited has a debt-to-equity ratio of 0.53, indicating that its debt is less than its equity. The book value per share stands at Rs 30.56.
Ownership & pledges
As of March 31, 2026, promoters held 65.0952% of the company's shares, with no shares pledged. Public shareholding was 31.4414%. Institutional holdings totaled 3.4634%, comprising 2.3935% by DIIs and 1.0699% by FIIs. The number of shareholders was 586.
Regulatory & surveillance
There is no information available regarding any regulatory or surveillance measures imposed on Onyx Biotec Limited.
Data as of — price: 2026-07-29 · financials: Mar 25 · shareholding: Mar 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.